Document:

exv10w23

EXHIBIT
10.23

EMPLOYMENT AGREEMENT

     The Employment Agreement (the “Agreement”) is made and entered into as of November
10, 2008 (the “Effective Date”) by and between RXi Pharmaceuticals Corporation, a
Delaware corporation (“RXi” or “Employer”), and Konstantinos Ioannou
Andrikopoulos, Ph.D., Esq., an individual and resident of the Commonwealth of Massachusetts
(“Employee”).

     WHEREAS, Employer and Employee desire to enter into an employment agreement under which
Employee shall serve on a full-time basis as RXi’s Legal Counsel and Chief IP Counsel, VP, on the
terms set forth in the Agreement, with the term of the Agreement to commence on the Effective Date.

     NOW, THEREFORE, upon the above premises, and in consideration of the mutual covenants and
agreements hereinafter contained, the parties hereto agree as follows.

     1. Engagement. Effective as of the Effective Date, Employer shall employ Employee, and
Employee shall serve, as RXi’s Legal Counsel and Chief IP Counsel, VP. As a condition to the
Employee’s employment by the Employer, Employee shall execute the Employee Confidentiality,
Non-Competition, and Proprietary Information Agreement, attached hereto as Exhibit 1 (the
“Confidentiality Agreement”).

     2. Duties. Employee shall perform all duties assigned to him by the Employer
faithfully, diligently and to the best of his ability. Such duties include, but are not limited
to, legal services related in any way to intellectual property, and general legal services.
Employee’s services hereunder shall be rendered at RXi’s office, except for travel when and as
required in the performance of Employee’s duties hereunder.

     3. Time and Efforts. Employee shall devote all of his business time, efforts,
attention and energies to Employer’s business and the discharge of his duties hereunder.

     4. Compensation. As the total consideration for Employee’s services rendered under the
Agreement, Employer shall pay or provide Employee the following compensation and benefits:

          4.1. Salary. Commencing on the Effective Date, Employee shall be entitled to receive
an annual Base Salary of Two Hundred and Forty Thousand Dollars ($240,000).

          4.2. Bonus. Employee shall receive an annual performance bonus for the achievement of
certain company and Employee performance goals, these goals will be established by the Compensation
Committee of the Employer’s Board of Directors. The bonus for top performance against these goals
shall be 25% of the annual Base Salary.

          4.3 Sign On Bonus. The Employee shall receive a $50,000 bonus in RXi’s first
regularly schedule payroll following the Effective Date.

          4.3. Stock Options. At the first regularly scheduled meeting of the Board of
Directors of the Employer following the Effective Date the Employer shall grant Employee stock
options (“Options”) under the RXi Pharmaceuticals 2007 Incentive Plan (the “Plan”) to purchase
100,000 shares. The Options shall vest in equal quarterly installments over 4 years beginning on
the first quarterly anniversary of the Effective Date of the Agreement provided, in each case, that
Employee remains in the continuous employ of Employer through such quarterly anniversary date.

 

 

Each vested Option shall (a) be exercisable at an exercise price equal to the fair market value at
the time of granting as determined by Employer’s Board of Directors, (b) have a term of ten years
and be exercisable by Employee at any time during such ten year period, and (c) be on such other
terms as shall be determined by Employer’s Board of Directors (or the Compensation Committee of the
Board) and set forth in a customary form of stock option agreement under the Plan evidencing the
Options. Upon the occurrence of a “Covered Transaction” (as defined in the Plan), the Options
shall thereupon vest in full and become exercisable as to all of the shares covered thereby in
accordance with the terms of the Plan.

          4.4. Expense Reimbursement. Employer shall reimburse Employee for reasonable and
necessary business expenses incurred by Employee in connection with the performance of Employee’s
duties in accordance with Employer’s usual practices and policies in effect from time to time.

          4.5. Vacation. Employee will be entitled to 25 days of paid “time off” (vacation days
plus sick time/personal time) for each full calendar year in accordance with the Company’s policies
from time to time in effect, in addition to holidays observed by the Company (for partial calendar
years, the Employee’s paid “time off” will be pro-rated). Paid time off may be taken at such times
and intervals as the Employee shall determine, subject to the business needs of the Company, and
otherwise shall be subject to the policies of the Company, as in effect from time to time. The
number of paid “time off” days will accrue per pay period and will stop accruing once 20 days have
been reached.

          4.7. Employee Benefits. Employee shall be eligible to participate in any medical
insurance and other employee benefits made available by Employer to all of its employees under its
group plans and employment policies in effect during the term of employment. Employee acknowledges
and agrees that, any such plans or policies now or hereafter in effect may be modified or
terminated by Employer at any time in its discretion.

          4.8. Payroll Taxes. Employer shall have the right to deduct from the compensation and
benefits due to Employee hereunder any and all sums required for social security and withholding
taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter
enacted or required as a charge on the compensation or benefits of Employee.

     5. Term. The Term of the Employee’s employment shall commence on the Effective Date
and shall conclude in accordance with Section 6.

     6. Termination. The Agreement may be terminated as set forth in this Section 6.

          6.1. Termination by Employer for Cause or Voluntary Resignation. Employer may
terminate Employee’s employment hereunder for Cause upon notice to Employee and Employee may
voluntarily resign his employment hereunder upon notice to Employer. “Cause” for the
purpose of this Agreement shall mean any of the following:

               (a) Employee’s breach of any material term of the Agreement; provided that the first
occasion of any particular breach shall not constitute such Cause unless Employee has failed
to cure such breach within ten (10) days after receiving written notice from Employer
stating the nature of such breach;

 

 

               (b) Employee’s conviction of, or plea of guilty or nolo contendere to, any felony or
other crime of moral turpitude;

               (c) Employee’s act of fraud or dishonesty materially injurious to Employer or its
reputation;

               (d) Employee’s continual failure or refusal to perform his material duties as required
under the Agreement after written notice from Employer stating the nature of such failure or
refusal and affording Employee at least ten days to correct the same;

               (e) Alcohol or drug abuse by Employee; or

               (f) Employee’s act or personal conduct that, in the reasonable, good faith judgment of
Employer’s Board of Directors (or a Committee of the Board), gives rise to a material risk
of liability of Employee or Employer under federal or applicable state law for
discrimination, or sexual or other forms of harassment, or other similar liabilities to
subordinate employees.

               Upon termination of Employee’s employment by Employer for Cause or by Employee due to a
voluntary resignation, all compensation and benefits to Employee hereunder shall cease and Employee
shall be entitled only to payment, not later than three days after the date of termination, of any
accrued but unpaid salary and unused vacation time as of the date of such termination.

          6.2. Termination by Employer without Cause or Resignation by Employee for “Good
Reason”. Employer may also terminate Employee’s employment without Cause upon notice to
Employee. The Employee may resign his employment with “Good Reason” upon notice to the Employer.
“Good Reason” means any of the following that shall occur without Employee’s written
consent: (i) any material breach of this Agreement by RXi or any successor to RXi that is not cured
within ten (10) days after RXi’s receipt of written notice from the Employee stating the nature of
such breach; (ii) a material reduction by RXi or any successor to RXi in the Employee’s job
responsibilities or duties; (iii) any diminution of base salary from the prior year, provided that
a diminution in the Employee’s base salary that is part of a broader reduction of salaries that
applies to all other senior managers of the Company shall not constitute Good Reason; or (iv) RXi’s
relocation of the Employee’s reporting location further than sixty (60) miles outside of Boston,
Massachusetts.

Upon termination of Employee’s employment by Employer without Cause ,or the Employee’s resignation
with “Good Reason” upon notice to Employer, all compensation and benefits to Employee hereunder
shall cease and Employee shall be entitled to payment of: (a) any accrued but unpaid salary and
unused vacation time (only as accrued during the term of employment) as of the date of such
termination; (b) six (6) months’ of salary from the date of termination (the “Severance
Period”) in the form of salary continuation; and (c) continued participation, at Employer’s
cost and expense, during the Severance Period in any Employer-sponsored group benefit plans in
which Employee was participating as of the date of termination

          6.3 Death or Disability. Employee’s employment will terminate automatically in the
event of Employee’s death or upon notice from Employer in event of his permanent disability.
Employee’s “permanent disability” shall have the meaning ascribed to such term in any
policy of disability insurance maintained by Employer (or Employee, as the case may be) with
respect to Employee, or if no such policy is then in effect, shall mean Employee’s inability to
fully perform his

 

 

duties hereunder with or without reasonable accommodation for any period of at least 75
consecutive days or for a total of 120 days, whether or not consecutive. Upon termination of
Employee’s employment as aforesaid, all compensation and benefits to Employee hereunder shall cease
and Employer shall pay to the Employee’s heirs or personal representatives, not later than ten days
after the date of termination, any accrued but unpaid salary and unused vacation as of the date of
such termination as required by law. In the event the Employer does not maintain short term and
long term disability policies as of the time of Employee’s termination due to “permanent
disability,” Employee shall be entitled to severance benefits specified in Section 6.2 above.

     7. Equitable Remedies; Injunctive Relief. Employee hereby acknowledges and agrees that
monetary damages are inadequate to fully compensate Employer for the damages that would result from
a breach or threatened breach of the Confidentiality Agreement and, accordingly, that Employer
shall be entitled to equitable remedies, including, without limitation, specific performance,
temporary restraining orders, and preliminary injunctions and permanent injunctions, to enforce
such Section without the necessity of proving actual damages in connection therewith. The
provision shall not, however, diminish Employer’s right to claim and recover damages or enforce any
other of its legal or equitable rights or defenses.

     8. Severable Provisions. The provisions of the Agreement are severable and if any one
or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the
remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall
nevertheless be binding and enforceable.

     9. Successors and Assigns. The Agreement shall inure to the benefit of and shall be
binding upon Employer, its successors and assigns and Employee and his heirs and representatives;
provided, however, that neither party may assign the Agreement without the prior written consent of
the other party.

     10. Entire Agreement. The Agreement including Exhibit 1 contains the entire agreement
of the parties relating to the subject matter hereof, and the parties hereto have made no
agreements, representations or warranties relating to the subject matter of the Agreement that are
not set forth otherwise therein or herein. Except as expressly provided herein, the Agreement
supersedes any and all prior or contemporaneous agreements, written or oral, between Employee and
Employer relating to the subject matter hereof. Any such prior or contemporaneous agreements are
hereby terminated and of no further effect, and Employee, by the execution hereof, agrees that any
compensation provided for under any such agreements is specifically superseded and replaced by the
provisions of the Agreement.

     11. Amendment. No modification of the Agreement shall be valid unless made in
writing, approved by the Compensation Committee and signed by the parties hereto and unless such
writing is made by an executive officer of Employer (other than Employee). The parties hereto
agree that in no event shall an oral modification of the Agreement be enforceable or valid.

     12. Governing Law. The Agreement is and shall be governed and construed in accordance
with the laws of the Commonwealth of Massachusetts without giving effect to the choice-of-law rules
of Massachusetts.

     13. Notice. All notices and other communications under the Agreement shall be in
writing and mailed, telecopied (in case of notice to Employer only) or delivered by hand or by a
nationally recognized courier service guaranteeing overnight delivery to a party at the following
address (or to

 

 

such other address as such party may have specified by notice given to the other party pursuant to
the provision):

     If to Employer:

	 	 	RXi Pharmaceuticals Corp.

60 Prescott Street

Worcester, MA 01605

     If to Employee:

     Though company e-mail or company regular mail box if employed by Company or if not employed:

	 	 	Konstantinos Ioannou Andrikopoulos, Ph.D.

55 Hillcrest Rd.

Reading, MA 01867

     14. Survival. Sections 7 through 16 shall survive the expiration or termination of
the Agreement.

     15. Counterparts. The Agreement may be executed in counterparts, each of which shall
be deemed to be an original and all of which together shall be deemed to be one and the same
agreement.

     16. Attorney’s Fees. In any action or proceeding to construe or enforce any provision
of the Agreement the prevailing party shall be entitled to recover its or his reasonable attorneys’
fees and other costs of suit in addition to any other recoveries.

IN WITNESS WHEREOF, the Agreement is executed as of the day and year first above written.

	 	 	 	 	 
	 	EMPLOYER

RXi Pharmaceuticals Corporation

 	 
	 	By:  	/s/ Tod Woolf 	 
	 	 	Tod Woolf 	 
	 	 	Chief Executive Officer

RXi Pharmaceuticals Corporation 	 
	 

	 	 	 	 	 
	EMPLOYEE

 	 	 
	/s/
Konstantinos Ioannou Andrikopoulos 	 	 
	Konstantinos Ioannou Andrikopoulos, Ph.D., Esq. 	 	 
	 	 	 

 

 

	 	 	 	 	 

Exhibit 1

RXi Pharmaceuticals Corporation

EMPLOYEE CONFIDENTIALITY, NON-COMPETITION, AND

PROPRIETARY INFORMATION AGREEMENT

AGREEMENT, effective as of November 10, 2008, between RXi Pharmaceuticals Corporation, a Delaware
corporation (the “Company”), and Konstantinos Ioannou Andrikopoulos, Ph.D., Esq. (the “Employee”).

1. Employee will make full and prompt disclosure to the Company of all inventions, improvements,
modifications, discoveries, methods, technologies, biological materials, and developments, and all
other materials, items, techniques, and ideas related directly or indirectly to the business of the
Company (all of which are collectively termed “Intellectual Property” hereinafter), whether
patentable or not, made or conceived by Employee or under Employee’s direction during Employee’s
employment with the Company, whether or not made or conceived during normal working hours, or on
the premises of the Company.

2. Employee agrees that all Intellectual Property, as defined above, shall be the sole property of
the Company and its assigns, and the Company and its assigns shall be the sole owner of all patents
and other rights in connection therewith. Employee hereby assigns to the Company any rights
Employee may have or acquire in all Intellectual Property and all related patents, copyrights,
trademarks, trade names, and other industrial and intellectual property rights and applications
therefore, in the United States and elsewhere. Employee further agrees that with regard to all
future developments of Intellectual Property, Employee will assist the Company in every way that
may be reasonably required by the Company (and at the Company’s expense) to obtain and, from time
to time, enforce patents on Intellectual Property in any and all countries that the Company may
require, and to that end, Employee will execute all documents for use in applying for and obtaining
such patents thereon and enforcing the same, as the Company may desire, together with any
assignment thereof to the Company or persons designated by the Company, and Employee hereby
appoints the Company as Employee’s attorney to execute and deliver any such documents or
assignments requested by the Company. Employee’s obligation to assist the Company in obtaining and
enforcing patents for Intellectual Property in any and all countries shall continue beyond the
termination of Employee’s employment with the Company, but the Company shall compensate Employee at
a reasonable, standard hourly rate following such termination for time directly spent by Employee
at the Company’s request for such assistance.

3. Employee hereby represents that Employee has no continuing obligation to assign to any former
employer or any other person, corporation, institution, or firm any Intellectual Property as
described above, other than possible assignment obligations owed to Shire Pharmaceuticals, Inc.
(“Shire”), his former employer. Employee does not believe that his obligations to Shire conflict
with the terms of this Confidentiality Agreement. Employee represents that Employee’s performance
of all the terms of this Agreement and as an employee of the Company does not and will not breach
any agreement to keep in confidence proprietary information acquired by

 

 

Employee, in confidence or in trust, prior to Employee’s employment by the Company. Employee has
not entered into, and Employee agrees not to enter into, any agreement (either written or oral),
which would put Employee in conflict with this Agreement.

4. Employee agrees to assign to the Company any and all copyrights and reproduction rights to any
material prepared by Employee in connection with this Agreement and/or developed during the term of
Employee’s employment with the Company.

5. Employee understands and agrees that a condition of Employee’s employment and continued
employment with the Company is that Employee has not brought and will not bring to the Company or
use in the performance of Employee’s duties at the Company any materials or documents rightfully
belonging to a former employer which are not generally available to the public.

6. Employee recognizes that the services to be performed by Employee hereunder are special, unique,
and extraordinary and that, by reason of Employee’s employment with the Company, Employee may
acquire Confidential Information (as hereinafter defined) concerning the operation of the Company,
the use or disclosure of which would cause the Company substantial loss and damage which could not
be readily calculated and for which no remedy at law would be adequate. Accordingly, Employee
agrees that Employee will not (directly or indirectly) at any time, whether during or after
Employee’s employment with the Company:

	 		 	(i) knowingly use for personal benefit or for any other reason not authorized by the
Company any Confidential Information that Employee may acquire or has acquired by
reason of Employee’s employment with the Company, or;

	 		 	(ii) disclose any such Confidential Information to any person or entity except (A) in
the performance of Employee obligations to the Company hereunder, (B) as required by a
court of competent jurisdiction, (C) in connection with the enforcement of Employee
rights under this Agreement, or (D) with the prior consent of the Board of Directors
of the Company.

     As used herein, “Confidential Information” includes information with respect to the facilities
and methods of the Company, reagents, chemical compounds, cell lines or subcellular constituents,
organisms, or other biological materials, trade secrets, and other Intellectual Property, systems,
patents and patent applications, procedures, manuals, confidential reports, financial information,
business plans, prospects, or opportunities, personnel information, or lists of customers and
suppliers; provided, however, that Confidential Information shall not include any information that
is known or becomes generally known or available publicly other than as a result of disclosure by
Employee which is not permitted as described in clause (ii) above, or the Company discloses same to
others without obtaining an agreement of confidentiality.

     Employee confirms that all Confidential Information is the exclusive property of the Company.
All business records, papers, documents and electronic materials kept or made by Employee relating
to the business of the Company which comprise Confidential Information shall be and remain the
property of the Company during the Employee’s employment and at all

 

 

times thereafter. Upon the termination, for any reason, of Employee’s employment with the Company,
or upon the request of the Company at any time, Employee shall deliver to the Company, and shall
retain no copies of any written or electronic materials, records and documents made by Employee or
coming into Employee’s possession concerning the business or affairs of the Company and which
comprise Confidential Information.

7. During the term of Employee’s employment with the Company (the “Restricted Period”), the
Employee shall not directly or indirectly, for Employee’s own account or for the account of others,
as an officer, director, stockholder (other than as the holder of less than 1% of the outstanding
stock of any publicly traded company), owner, partner, employee, promoter, consultant, manager or
otherwise participate in the promotion, financing, ownership, operation, or management of, or
assist in or carry on through proprietorship, a corporation, partnership, or other form of business
entity which is in competition with the Company within the United States or any other country in
which the Company is conducting or is actively seeking or planning to conduct business as of the
date of such termination. Provided, however, that nothing herein shall be deemed to restrict the
Employee in the practice of law.

     During the Restricted Period, the Employee shall not, whether for Employee’s own account or
for the account of any other person (excluding the Company):

	 	(i)	 	solicit or contact in an effort to conduct non-legal business with any person
who was or is a customer of the Company during the term of this Agreement or after its
termination, or any affiliate of any such person, if such solicitation or contact is
for the purpose of competition with the Company; or

	 	(ii)	 	solicit or induce any of the Company’s employees to leave their employment with
the Company or accept employment with anyone else, or hire any such employees or
persons who were employed by the Company during the preceding twelve (12) months.

     Nothing herein shall prohibit or preclude the Employee from performing any other types of
services that are not precluded by this Section 7 for any other person.

     Employee has carefully read and considered the provisions of this Section 7 (including the
Restricted Period, scope of activity to be restrained, and the restriction’s geographical scope)
and concluded them to be fair, appropriate and reasonably required for the protection of the
legitimate business interests of the Company, its officers, directors, employees, creditors, and
shareholders. Employee understands that the restrictions contained in this Section may limit
Employee’s ability to engage in a non-legal business similar to the Company’s business, but
acknowledges that Employee will receive adequate and affluent remuneration and other benefits from
the Company hereunder to justify such restrictions.

     The Employee shall give prompt notice to the Company of the Employee’s acceptance of
employment or other fees for services relationship during the Restricted Period provided that

 

 

such disclosure is consistent with his obligations as an attorney, which notice shall include
the name of, the business of, and the position that Employee shall hold with such other employer.

8. In the event that Employee’s employment is transferred by the Company to a subsidiary,
affiliated company, or acquiring company (as the case may be), Employee’s employment by such
company will, for the purpose of this Agreement, be considered as continued employment with the
Company, unless Employee executes an agreement, substantially similar in substance to this
Agreement, and until the effective date of said agreement in any such company for which Employee
becomes employed. It is further agreed that changes in Employee’s position or title unless
expressly agreed to in writing will operate to terminate this Agreement without Cause .

9. Upon termination of Employee’s employment for any reason, unless such employment is transferred
to a subsidiary, affiliated or acquiring company of the Company, Employee agrees to leave with, or
return to, the Company all records, drawings, notebooks, and other documents pertaining to the
Company’s Confidential Information, whether prepared by Employee or others, as well as any
equipment, tools or other devices owned by the Company, that are then in Employee’s possession,
however such items were obtained, and Employee agrees not to reproduce or otherwise retain any
document or data relating thereto.

10. Employee obligations under this Agreement shall survive the termination of Employee’s
employment with the Company regardless of the manner of, and reason for, such termination, and
shall be binding upon Employee’s heirs, executors, and administrators.

11. Prior to entering the employ of the Company, Employee has lawfully terminated employment with
all previous employers. Subject to paragraph 6 of the Employment Agreement, Employee acknowledges
that this Agreement does not constitute a contract of employment for a term and does not otherwise
imply that the Company will continue his or her employment for any period of time. Employee
further understands and agrees that no license to any of the Company’s trademarks, patents,
copyrights or other proprietary rights is either granted or implied by Employee’s access to and
utilization of the Confidential Information or Intellectual Property.

12. No delay or omission by the Company in exercising any right under this Agreement will operate
as a waiver of that or any other right. A waiver or consent given by the Company on any one
occasion is effective only in that instance and will not be construed as a bar to or waiver of any
right on any other occasion.

13. Employee agrees that in addition to any other rights and remedies available to the Company for
any breach or threatened breach by Employee of Employee’s obligations hereunder, the Company shall
be entitled to enforcement of Employee’s obligations hereunder by whatever means are at the
Company’s disposal, including court injunction.

 

 

14. The Company may assign this Agreement to any other corporation or entity which acquires
(whether by purchase, merger, consolidation or otherwise) all or substantially all of the business
and/or assets of the Company. Employee shall have no rights of assignment.

15. If any provision of this Agreement shall be declared invalid, illegal, or unenforceable, then
such provision shall be enforceable to the extent that a court deems it reasonable to enforce such
provision. If such provision shall be unreasonable to enforce to any extent, such provision shall
be severed and all remaining provisions shall continue in full force and effect.

16. This Agreement shall be effective as of the date first written above.

17. This Agreement shall be governed in all respects by the laws of the Commonwealth of
Massachusetts. Each of the Company and Employee (a) hereby irrevocably submits to the exclusive
jurisdiction of the state courts of The Commonwealth of Massachusetts or the United States District
Court located in The Commonwealth of Massachusetts for the purpose of any action between the
Company and Employee arising in whole or in part under or in connection with this Agreement, (b)
hereby waives, to the extent not prohibited by applicable law, and agrees not to assert, by way of
motion, as a defense or otherwise, in any such action, any claim that it is not subject personally
to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that any such action brought in one of the above-named courts should be
dismissed on grounds of forum non conveniens, should be transferred or removed to any court other
than one of the above-named courts, or should be stayed by reason of the pendency of some other
proceeding in any other court other than one of the above-named courts, or that this Agreement or
the subject matter hereof may not be enforced in or by such court, and (c) hereby agrees not to
commence any such action other than before one of the above-named courts. Notwithstanding the
previous sentence, the Company or Employee may commence any action in a court other than the
above-named courts solely for the purpose of enforcing an order or judgment issued by one of the
above-named courts.

IN WITNESS WHEREOF, Employee has executed this Agreement under seal as of the date set forth above:

	 	 	 	 	 
	 	 	 
	BY:  	/s/
Konstantinos Ioannou Andrikopoulos 	 	 

Name of
Employee: Konstantinos Ioannou
Andrikopoulos, Ph.D., Esq.

	 	 	 	 	 
	ACCEPTED AND AGREED TO:

RXi Pharmaceuticals Corporation

 	 	 
	BY:  	/s/ Tod Woolf 	 	 
	 	Name:  	Tod Woolf 	 	 
	 	Title:  	President and CEO, Ph.D.EX-4.1

Exhibit 4.1

CARDIOVASCULAR SYSTEMS, INC.

REGISTRATION RIGHTS AGREEMENT

          THIS REGISTRATION RIGHTS AGREEMENT is made as of the 16th day of March, 2009, by and between
Cardiovascular Systems, Inc., formerly known as Replidyne, Inc., a Delaware corporation (the
“Company”), and the stockholders and other securityholders of the Company listed on
Schedule I, each of which is referred to in this Agreement as an “Investor.”

RECITALS

          WHEREAS, Cardiovascular Systems, Inc., a Minnesota corporation (“CSI-MN”), entered
into an Agreement and Plan of Merger and Reorganization, dated November 3, 2008 (the “Merger
Agreement”) with the Company and Responder Merger Sub, Inc., a Minnesota corporation and
wholly-owned subsidiary of the Company, pursuant to which CSI-MN became a wholly-owned subsidiary
of the Company, the CSI-MN common stock was converted into shares of Company common stock, and the
Company changed its name from Replidyne, Inc. to “Cardiovascular Systems, Inc.” (the transactions
contemplated by the Merger Agreement are referred to herein as the “Merger”);

          WHEREAS, prior to the Merger, the Investors either (i) held shares of CSI-MN’s Series A
convertible preferred stock, Series A-1 convertible preferred stock and/or Series B convertible
preferred stock (collectively, the “Preferred Stock”), which provided them certain rights
and preferences (the “CSI Investors”), or (ii) were parties to that certain Fourth Amended
and Restated Stockholders Agreement, dated August 17, 2005, by and among the Company and certain
Company stockholders and warrant holders, as amended March 7, 2006 (the “Replidyne Stockholders
Agreement”) (the “Replidyne Investors”);

          WHEREAS, as a condition precedent to the Merger Agreement, CSI-MN obtained an agreement from
the holders of the Preferred Stock that all shares of Preferred Stock would convert into shares of
CSI-MN common stock immediately prior to the Merger (the “Stockholder Conversion
Agreement”), which Stockholder Conversion Agreement also provided that the Investor’s Rights
Agreement of CSI-MN (the “CSI Investor’s Rights Agreement”) would terminate upon the
closing of the Merger;

          WHEREAS, due to their relationship with and percentage ownership in the combined company after
the closing of the Merger, the CSI Investors will be subject to resale restrictions imposed by the
federal securities laws;

          WHEREAS, in order to induce the CSI Investors to enter into the Stockholder Conversion
Agreement, CSI-MN agreed to provide the CSI Investors with registration rights after the Merger
which are comparable to those to which they were entitled prior to the Merger in their capacity as
holders of CSI-MN Preferred Stock under the CSI Investor’s Rights Agreement;

          WHEREAS, under the Replidyne Stockholders Agreement, the registration rights under Articles 3
and 4 thereof shall terminate as to any holder upon the date on which such holder holds less than
1% of the outstanding capital stock and all shares held by such holder can be resold pursuant to
Rule 144;

 

 

          WHEREAS, as a result of the Merger, the Replidyne Investors will be the only parties to the
Replidyne Stockholders Agreement who each hold more than 1% of the outstanding capital stock of the
Company or as to whom all shares held by such holders cannot be resold pursuant to Rule 144, and
the Replidyne Investors wish to terminate their rights under the Replidyne Stockholders Agreement
and replace them with the registration rights hereunder;

          WHEREAS, the Merger closed on February 25, 2009 and the Parties desire to memorialize the
registration rights of the Investors.

          NOW, THEREFORE, IN CONSIDERATION of the foregoing and the mutual covenants contained in this
Agreement, and for other good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, the Company and the Investors agree as follows:

DEFINITIONS

     As used in this Agreement, the following terms shall have the following respective meanings:

          “Agreement” shall mean this Registration Rights Agreement and all schedules and
exhibits, if any, attached to this agreement, in each case as they may be supplemented, amended,
restated or replaced from time to time, and the expressions “hereof”, “herein”,
“hereto”, “hereunder”, “hereby” and similar expressions refer to this
Agreement; and unless otherwise indicated, references to Sections, Schedules and Exhibits are to
the specified Sections, Schedules and Exhibits, if any, of this Agreement.

          “Board of Directors” shall mean the board of directors of the Company as constituted
from time to time.

          “Commission” shall mean the Securities and Exchange Commission, or any other federal
agency at the time administering the Securities Act.

          “Common Stock” shall mean the Common Stock, $0.001 per share, of the Company.

          “Easton” shall mean Easton Capital Partners, LP and Easton Hunt Capital Partners,
L.P., collectively.

          “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any
similar federal statute, and the rules and regulations of the Commission thereunder, all as the
same shall be in effect at the time.

          “Investor Securities” shall mean (i) all shares of Common Stock held by each Investor
immediately after the closing of the Merger, (ii) all shares of Common Stock issuable upon the
conversion and/or exercise of outstanding options and warrants held by each Investor immediately
after the closing of the Merger, and (iii) any shares of Common Stock issued as (or issuable upon
the conversion or exercise of any warrant, right or other security which is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of, the Common Stock
referred to in (i) or (ii), as the case may be; provided, however, that Investor

2

 

Securities shall not include those securities (x) that have been effectively registered under
Section 5 of the Securities Act and disposed of pursuant to an effective registration statement, or
(y) that have been transferred pursuant to Rule 144 under the Securities Act or any successor rule
such that, after any such transfer referred to in this clause (y), such securities may be freely
transferred without restriction under the Securities Act.

          “Maverick” shall mean Maverick Fund LDC, Maverick Fund USA, Ltd. and Maverick Fund II,
Ltd., collectively.

          “Party” shall mean a party hereto from time to time.

          “Permissible Transferee” shall mean an affiliate of an Investor; provided,
however, that Permissible Transferees shall not include affiliates of an Investor who
acquire Investor Securities (i) that have been effectively registered under Section 5 of the
Securities Act and disposed of pursuant to an effective registration statement, or (ii) that have
been transferred pursuant to Rule 144 under the Securities Act or any successor rule such that,
after any such transfer referred to in this clause (ii), such securities may be freely transferred
without restriction under the Securities Act.

          “Person” shall mean any individual, corporation, partnership, limited liability
company, limited liability partnership, firm, joint venture, association, joint-stock company,
unincorporated organization, trust, trustee, executor, administrator or other legal personal
representative, regulatory body or agency, government or governmental agency, authority or other
entity howsoever designated or constituted.

          “register,” “registered” and “registration” shall mean a registration
effected by preparing and filing a registration statement or statements or similar documents in
compliance with the Securities Act and the declaration or ordering of effectiveness of such
registration statement or document by the Commission.

          “Requisite Period” shall mean, with respect to a firm commitment underwritten public
offering, the period commencing on the effective date of the registration statement and ending on
the date each underwriter has completed the distribution of all securities purchased by it, and,
with respect to any other registration, the period commencing on the effective date of the
registration statement and ending on the earlier of the date on which the sale of all Investor
Securities covered thereby is completed or 180 days after such effective date.

          “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar
federal statue, and the rules and regulations of the Commission thereunder, all as the same shall
be in effect at the applicable time.

          1. Automatic and Demand Registration.

               (a) If the Company shall receive, at any time after six (6) months after the closing of the
Merger, a written request (the “Demand Notice”) from an Investor or Investors holding no
less than an aggregate of 20% of the then outstanding Investor Securities that the Company at its
own expense file a registration statement under the Securities Act on Form S-1 covering the
registration of the Investor Securities, then the Company shall comply with the requirements set
forth in Section 1(b).

3

 

               (b) Within ten (10) days of receipt of any Demand Notice under Section 1(a), the Company shall
give written notice (a “Company Notice”) to all Investors from whom a Demand Notice has not
been received and shall use its reasonable best efforts to register under the Securities Act, in
accordance with the method of disposition specified in the Demand Notice, the number of the
Investor Securities specified in the Demand Notice (and in all notices received by the Company from
other Investors within twenty (20) days after the giving of such Company Notice). If the method of
disposition specified in the Demand Notice is an underwritten public offering, the right of any
Investor to include its Investor Securities in such registration shall be conditioned upon such
Investor’s participation in such underwriting and the inclusion of such Investor’s Investor
Securities in the underwriting to the extent provided herein. All Investors proposing to
distribute their securities through such underwriting (the “Offering Investors”) shall,
together with the Company as provided by Section 4(J), enter into an underwriting agreement (in
such form and containing such provisions as provided by Section 4(J) with the underwriter or
underwriters selected for such underwriting). Notwithstanding any other provision of this Section
1, if the managing underwriter advises the Offering Investors in writing that in its opinion,
marketing factors require a limitation of the number of shares to be underwritten, then the number
of shares of such Investor Securities that may be included in the underwriting shall be reduced pro
rata as between the Offering Investors thereof based upon the number of Investor Securities owned
by each such Investor; provided, however, that the number of shares of Investor
Securities to be included in such underwriting shall not be reduced unless all other securities are
first entirely excluded from the underwriting. The Company shall have the right to delay the
filing of the Form S-1 registration statement for a period not to exceed one hundred twenty (120)
days if the Board of Directors of the Company shall have determined, in good faith, that to so file
the Form S-1 registration statement would be seriously detrimental to the Company and its
stockholders, and the President of the Company has agreed and delivered to the holder(s) a
certificate to such effect; provided, however, that the Company may not utilize
this right more than once in any twelve (12) month period; and provided further,
that the Company shall not register any securities for its own account or that of any other
stockholder during such one hundred twenty (120) day period.

               (c) The Company shall be obligated to register Investor Securities pursuant to Section 1(b) on
three (3) occasions; provided, that each such obligation shall be deemed satisfied only
when a registration statement covering all Investor Securities specified in notices received as
aforesaid, for sale in accordance with the method of disposition specified in the Demand Notice,
shall have become effective and, if such method of disposition is a firm commitment underwritten
public offering, all such Investor Securities shall have been sold pursuant thereto.

          2. Piggyback Registration.

               (a) If the Company at any time (other than pursuant to Sections 1 or 3) proposes to register
any of its securities under the Securities Act for sale to the public, whether for its own account
or for the account of other security holders or both (except with respect to registration
statements on Forms S-4 and S-8 and any similar successor forms) (a “Piggyback
Registration”), each such time it will give prompt written notice to such effect to all holders
of outstanding Investor Securities at least thirty (30) days prior to such filing. Upon the
written request of any holder of Investor Securities, received by the Company within twenty (20)
days after the giving of any such notice by the Company, to register any of such holder’s Investor

4

 

Securities (the “Piggyback Notices”), the Company will, subject to Section 2(b), cause
all Investor Securities as to which registration shall have been so requested pursuant to the
Piggyback Notices to be included in the securities to be covered by the registration statement
proposed to be filed by the Company, all to the extent requisite to permit the sale or other
disposition by the holder of such Investor Securities so registered. Notwithstanding the foregoing
provisions, the Company may withdraw any registration statement referred to in this Section 2
without thereby incurring any liability to the holders of Investor Securities.

               (b) In the event that any Piggyback Registration shall be, in whole or in part, an
underwritten public offering of Common Stock and the managing underwriter advises the holders of
Investor Securities participating therein in writing that in their opinion marketing factors
require a limitation of the number of shares to be underwritten, then the number of shares of such
Investor Securities that may be included in the underwriting shall be reduced pro rata as between
the holders thereof based upon the number of Investor Securities owned by each such holder;
provided, however, that the number of shares of Investor Securities to be included
in such underwriting shall not be reduced unless all other securities other than those to be issued
by the Company are first entirely excluded from the underwriting; provided further,
that the aggregate value of the Investor Securities to be included in such registration may not be
so reduced to less than thirty percent (30%) of the total value of all Investor Securities
requested to be included in such registration pursuant to the Piggyback Notices.

          3. Registration on Form S-3. In addition to the rights under Section 2 hereof, if at any
time:

	 	(A)	 	a holder or holders of Investor Securities then outstanding request(s) that the
Company file a registration statement on Form S-3 or any successor thereto for a public
offering of all or any portion of the Investor Securities held by such requesting
holder or holders, the reasonably anticipated aggregate price to the public of which
would exceed $1,000,000; and
	 
	 	(B)	 	the Company is a registrant entitled to use Form S-3 or any successor thereto
to register such Investor Securities,

then the Company shall use its reasonable best efforts to register under the Securities Act on Form
S-3 or any successor thereto, in accordance with the method of disposition specified in such
notice, the number of Investor Securities specified in such notice. Whenever the Company is
required by this Section 3 to use its reasonable best efforts to effect the registration of
Investor Securities, each of the procedures and requirements of Section 1 (including the
requirement that the Company notify all holders of Investor Securities from whom notice has not
been received and provide them with the opportunity to participate in the offering) shall apply to
such registration. In addition, the Company shall have the right to delay the filing of the Form
S-3 registration statement for a period not to exceed one hundred twenty (120) days if the Board of
Directors of the Company shall have determined, in good faith, that to so file the Form S-3
registration statement would be seriously detrimental to the Company and its stockholders, and the
President of the Company has agreed and delivered to the holder(s) a certificate to such effect;
provided, however, that the Company may not utilize this right more than once in
any twelve (12) month period; and provided further, that the Company shall not
register any securities for its own account or that of any other stockholder during such one
hundred twenty

5

 

(120) day period. The Company shall be obligated to register Investor Securities pursuant to this
Section 3 on multiple occasions; provided, that such obligation shall be deemed satisfied
on any occasion only when a registration statement covering all Investor Securities specified in
notices received as aforesaid, for sale in accordance with the method of disposition specified by
the requesting holders, shall have become effective and, if such method of disposition is a firm
commitment underwritten public offering, all such Investor Securities shall have been sold pursuant
thereto.

          4. Registration Procedures. If and whenever the Company is required by the provisions of
Sections 1, 2 or 3 to use its reasonable best efforts to effect the registration of any Investor
Securities under the Securities Act, the Company will, as soon as practical:

	 	(A)	 	prepare and file with the Commission a registration statement with respect to
such securities within ninety (90) days after delivery of a Demand Notice under Section
1, or forty-five (45) days after delivery of a Demand Notice under Section 3, and use
its reasonable best efforts to cause such registration statement to become effective
not later than ninety (90) days from the date of its filing and to remain effective for
the Requisite Period; provided, however, that (i) the Requisite Period
shall be extended for a period of time equal to the period the holder of Investor
Securities refrains, at the request of an underwriter of Common Stock (or other
securities) of the Company, from selling any securities included in such registration,
and (ii) in the case of any registration of Investor Securities on Form S-3 that are
intended to be offered on a continuous or delayed basis, subject to compliance with
applicable Commission rules, the Requisite Period shall be extended for up to sixty
(60) days, if necessary, to keep the registration statement effective until all such
Investor Securities are sold;
	 
	 	(B)	 	prepare and file with the Commission such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be
necessary to keep such registration statement effective for the Requisite Period and
comply with the provisions of the Securities Act with respect to the disposition of all
Investor Securities covered by such registration statement in accordance with the
intended method of disposition set forth in such registration statement for such
period;
	 
	 	(C)	 	furnish to each seller of Investor Securities and to each underwriter such
number of copies of the registration statement and the prospectus included therein
(including each preliminary prospectus) as such Persons reasonably may request in order
to facilitate the intended disposition of the Investor Securities covered by such
registration statement;
	 
	 	(D)	 	use its reasonable best efforts to (i) register or qualify the Investor
Securities covered by such registration statement under the securities or “blue sky”
laws of such jurisdictions as the sellers of Investor Securities or, in the case of an
underwritten public offering, the managing underwriter reasonably shall request; (ii)
prepare and file in those jurisdictions such amendments (including post effective
amendments) and supplements, and take such other actions, as may be necessary to
maintain such registration and qualification in effect at all times for

6

 

	 	 	 	the period of distribution contemplated thereby; and (iii) take such further action
as may be necessary or advisable to enable the disposition of the Investor
Securities in such jurisdictions; provided, that the Company shall not for
any such purpose be required to qualify generally to transact business as a foreign
corporation in any jurisdiction where it is not so qualified or to consent to
general service of process in any such jurisdiction;
	 
	 	(E)	 	use its reasonable best efforts to list the Investor Securities covered by such
registration statement with any securities exchange on which the Common Stock of the
Company is then listed;
	 
	 	(F)	 	immediately notify each seller of Investor Securities and each underwriter
under such registration statement, at any time when a prospectus relating thereto is
required to be delivered under the Securities Act, of the happening of any event of
which the Company has knowledge as a result of which the prospectus contained in such
registration statement, as then in effect, includes any untrue statement of a material
fact or omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in light of the circumstances then existing
and promptly amend or supplement such registration statement to correct any such untrue
statement or omission;
	 
	 	(G)	 	notify each seller of Investor Securities of the issuance by the Commission of
any stop order suspending the effectiveness of the registration statement or the
initiation of any proceedings for that purpose and make every reasonable effort to
prevent the issuance of any stop order and, if any stop order is issued, to obtain the
lifting thereof at the earliest possible time;
	 
	 	(H)	 	permit a single firm of counsel, designated as selling stockholders’ counsel by
the Offering Investors holding a majority of the Investor Securities to be registered,
to review the registration statement and all amendments thereto for a reasonable period
of time prior to their filing (provided, however, that in no event
shall the Company file any document in a form to which such counsel reasonably objects;
and provided further, that the Company shall have no obligation to
permit such counsel to review any prospectus supplements prior to their filing, unless,
and only to the extent, that any prospectus supplement contains changes to information
in the registration statement relating to the Offering Investors);
	 
	 	(I)	 	make generally available to its security holders as soon as practicable, but
not later than ninety (90) days after the close of the period covered thereby, an
earnings statement (in form complying with the provisions of Rule 158 under the
Securities Act) covering a twelve (12) month period beginning not later than the first
day of the Company’s next fiscal quarter following the effective date of the
registration statement;
	 
	 	(J)	 	if the offering is an underwritten offering, the Company will enter into a
written agreement with the managing underwriter selected in the manner herein provided
in such form and containing such provisions as are usual and customary in the
securities business for such an arrangement between such underwriter and

7

 

	 	 	 	companies of the Company’s size and investment stature, including customary
holdback, indemnification and contribution provisions;
	 
	 	(K)	 	if the offering is an underwritten offering, at the request of any seller of
Investor Securities, use its reasonable best efforts to furnish to such seller on the
date that Investor Securities are delivered to the underwriters for sale pursuant to
such registration: (i) a copy of an opinion dated such date of counsel representing
the Company for the purposes of such registration, addressed to the underwriters, and
subject to customary qualifications stating (A) that such registration statement has
become effective under the Securities Act, (B) that to the knowledge of such counsel,
no stop order suspending the effectiveness thereof has been issued and no proceedings
for that purpose have been instituted or are pending or contemplated under the
Securities Act, (C) that the registration statement, the related prospectus and each
amendment or supplement thereof comply, and as of their respective issue dates
complied, as to form in all material respects with the requirements of the Securities
Act (except that such counsel need not express any opinion as to the financial
statements or other financial or statistical information contained therein) and (D) to
such other effects as reasonably may be requested by counsel for the underwriters, and
(ii) a copy of a letter dated such date from the independent public accountants
retained by the Company, addressed to the underwriters, stating that they are
independent public accountants within the meaning of the Securities Act and that, in
the opinion of such accountants, the financial statements of the Company included in
the registration statement or the prospectus, or any amendment or supplement thereof,
comply as to form in all material respects with the applicable accounting requirements
of the Securities Act, and such letter shall additionally cover such other financial
matters (including information as to the period ending no more than five (5) business
days prior to the date of such letter) with respect to such registration as such
underwriters reasonably may request;
	 
	 	(L)	 	upon reasonable advance notice and during normal business hours, make available
for inspection by each seller of Investor Securities, any underwriter participating in
any distribution pursuant to such registration statement, and any attorney, accountant
or other agent retained by such seller or underwriter, all financial and other records,
pertinent corporate documents and properties of the Company, and cause the Company’s
officers, directors and employees to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant or agent in connection with such
registration statement;
	 
	 	(M)	 	provide a transfer agent and registrar, which may be a single entity, and
provide a CUSIP number for all such Investor Securities, in each case not later than
the effective date of the registration statement;
	 
	 	(N)	 	take all actions reasonably necessary to facilitate the timely preparation and
delivery of certificates (not bearing any legend restricting the sale or transfer of
such securities) representing the Investor Securities to be sold pursuant to the
registration statement and to enable such certificates to be in such denominations

8

 

	 	 	 	and registered in such names as the Sellers or any underwriters may reasonably
request;
	 
	 	(O)	 	take all other reasonable actions necessary to expedite and facilitate the
registration of the Investor Securities pursuant to the registration statement;
	 
	 	(P)	 	notify each selling Investor, promptly after the Company receives notice
thereof, of the time when such registration statement has been declared effective or a
supplement to any prospectus forming a part of such registration statement has been
filed; and
	 
	 	(Q)	 	after such registration statement becomes effective, notify each selling
Investor of any request by the SEC that the Company amend or supplement such
registration statement or prospectus.

          In connection with each registration hereunder, the sellers of Investor Securities will
furnish to the Company in writing such information with respect to themselves and the proposed
distribution by them as reasonably shall be necessary in order to assure compliance with federal
and applicable state securities laws.

          5. Expenses. All expenses incurred by the Company in complying with Sections 1, 2 and 3,
including all registration and filing fees, printing expenses, fees and disbursements of counsel
and independent public accountants for the Company, fees and expenses (including counsel fees)
incurred in connection with complying with state securities or “blue sky” laws, fees of the
Financial Industry Regulatory Authority, fees of transfer agents and registrars, costs of insurance
and reasonable fees and disbursements of one counsel for the sellers of Investor Securities, as a
group, selected by them, but excluding any Selling Expenses, are called “Registration
Expenses.” All underwriting discounts and selling commissions applicable to the sale of
Investor Securities are called “Selling Expenses.” The Company will pay all Registration
Expenses in connection with each registration statement under Sections 1, 2 and 3. All Selling
Expenses in connection with each registration statement under Sections 1, 2 or 3 shall be borne by
the Holders of Investor Securities in proportion to the number of Investor Securities sold by each
or as they may otherwise agree.

          6. Indemnification and Contribution.

               (a) In the event of a registration of any of the Investor Securities under the Securities Act
pursuant to Sections 1, 2 or 3, the Company will indemnify and hold harmless each seller of such
Investor Securities thereunder and the partners, members, officers, directors and stockholders of
each such seller; any underwriter (as defined in the Securities Act), legal counsel and accountants
for each such seller; and each other Person, if any, who controls such seller or underwriter within
the meaning of the Securities Act or the Exchange Act, from and against, and pay or reimburse them
for, any losses, claims, reasonable expenses, damages or liabilities, joint or several, to which
any of the aforementioned Persons may become subject under the Securities Act, the Exchange Act or
otherwise, insofar as such losses, claims, expenses, damages or liabilities (or actions in respect
thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any
material fact contained in any registration statement under which such Investor Securities were
registered under the Securities Act pursuant

9

 

to Sections 1, 2 or 3, any preliminary prospectus or final prospectus contained therein, or
any amendment or supplement thereof, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, or any violation or alleged violation of the Securities Act, the
Exchange Act, any state securities or blue sky laws and specifically will reimburse each of the
aforementioned Persons for any legal or other expenses reasonably incurred by it in connection with
investigating or defending any such loss, claim, damage, liability or action; provided,
that the Company will not be liable in any such case if and to the extent that any such loss,
claim, expense, damage or liability arises out of or is based upon the Company’s reliance on an
untrue statement or alleged untrue statement or omission or alleged omission so made in conformity
with information furnished by any such seller, underwriter or controlling Person in writing
specifically for use in such registration statement or prospectus; and provided
further, that the Company shall not be liable to the extent that any such loss, claim,
expense, damage or liability (or action in respect thereof) arises out of or is based upon an
untrue statement or alleged untrue statement or omission in such registration statement corrected
in an amendment or supplement to the registration statement, such amendment or supplement was
delivered to the indemnified party in sufficient quantities and a reasonable period of time prior
to the closing of any offering and the indemnified party failed to deliver or failed to cause to be
delivered such registration statement as so amended or supplemented to the Person asserting such
loss, claim, expense, damage or liability.

               (b) In the event of a registration of any of the Investor Securities under the Securities Act
pursuant to Sections 1, 2 or 3, each seller of such Investor Securities thereunder, severally and
not jointly, will indemnify and hold harmless the Company, each Person, if any, who controls the
Company within the meaning of the Securities Act, each officer of the Company who signs the
registration statement, each director of the Company and any underwriter and any controlling Person
of such underwriter from and against all losses, claims, reasonable expenses, damages or
liabilities, joint or several, to which the Company or such officer, director, underwriter or
controlling Person may become subject under the Securities Act, Exchange Act or otherwise, insofar
as such losses, claims, expenses, damages or liabilities (or actions in respect thereof) arise out
of or are based upon reliance on any untrue statement or alleged untrue statement of any material
fact contained in the registration statement under which such Investor Securities were registered
under the Securities Act pursuant to Sections 1, 2 or 3, any preliminary prospectus or final
prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, and will reimburse the Company
and each such officer, director, underwriter and controlling Person for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any such loss, claim,
expense, damage, liability or action; provided, that such seller will be liable hereunder
in any such case if and only to the extent that any such loss, claim, expense, damage or liability
arises out of or is based upon an untrue statement or alleged untrue statement or omission or
alleged omission made in reliance upon and in conformity with information pertaining to such
seller, as such, furnished in writing to the Company by such seller specifically for use in such
registration statement or prospectus; and provided further, that the liability of
each seller hereunder shall be limited to the proportion of any such loss, claim, expense, damage
or liability which is equal to the proportion that the public offering price of the Investor
Securities sold by such seller under such registration statement bears to the total public offering
price of all securities sold thereunder, but not in any event to

10

 

exceed the proceeds received by such seller from the sale of Investor Securities covered by
such registration statement. Notwithstanding the foregoing, the indemnity provided in this Section
6(b) shall not apply to amounts paid in settlement of any such loss, claim, expense, damage or
liability if such settlement is effected without the consent of such seller.

               (c) Promptly after receipt by an indemnified party hereunder of notice of the commencement of
any action (including any governmental action), such indemnified party shall, if a claim in respect
thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in
writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any
liability which it may have to such indemnified party other than under this Section 6 and shall
only relieve it from any liability which it may have to such indemnified party under this Section 6
if and to the extent the indemnifying party is materially prejudiced by such omission. In case any
such action shall be brought against any indemnified party and it shall notify the indemnifying
party of the commencement thereof, the indemnifying party shall be entitled to participate in and,
to the extent it shall wish, to jointly with any other indemnifying party similarly notified,
assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and,
after notice from the indemnifying party to such indemnified party of its election so to assume and
undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party
under this Section 6 for any legal expenses subsequently incurred by such indemnified party in
connection with the defense thereof other than reasonable costs of investigation and of liaison
with counsel so selected; provided, that if the defendants in any such action include both
the indemnified party and the indemnifying party and the indemnified party shall have reasonably
concluded that there may be reasonable defenses available to it which are different from or
additional to those available to the indemnifying party or if the interests of the indemnified
party reasonably may be deemed to conflict with the interests of the indemnifying party, the
indemnified party shall have the right to select a separate counsel and to assume such legal
defenses and otherwise to participate in the defense of such action, with the reasonable expenses
and fees of such separate counsel and other expenses related to such participation to be reimbursed
by the indemnifying party as incurred. In no event shall the indemnifying party be obligated to
bear the expenses of more than one counsel for the indemnified party or parties, plus local
counsel, if necessary, pursuant to the preceding sentence.

               (d) If the indemnification provided for in this Section 6 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss, claim, expense,
damage or liability referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such loss, claim, expense, damage or liability in such proportion as is
appropriate to reflect the relative fault of the indemnifying party, on the one hand, and of the
indemnified party, on the other, in connection with the untrue statement or alleged untrue
statement or omission or alleged omission or violation or alleged violation that resulted in such
loss, claim, expense, damage or liability as well as any other relevant equitable considerations.
The relative fault of the indemnifying party and of the indemnified party shall be determined by
reference to, among other things, whether the untrue statement or alleged untrue statement or
omission or alleged omission or violation or alleged violation relates to information supplied or
acts or omissions by the indemnifying party or by the indemnified party and the parties’ relative
intent, knowledge, access to information, and opportunity to correct or prevent such statement,
omission or violation; provided, that, in no event shall any contribution of a

11

 

holder of Investor Securities under this Section 6 exceed the net proceeds from the offering
received by such holder.

               (e) The obligations of the Parties under this Section 6 shall survive the completion of any
offering of Investor Securities in a registration statement under Section 1, 2 or 3;
provided, that any such indemnification obligations shall not extend beyond the period
proscribed by the applicable statute of limitations (and all extensions thereof) with respect to
such action or claim; and provided further, that if notice is given under this
Section 6 with respect to any matter entitling a party to indemnification hereunder prior to the
applicable expiration date, such indemnification obligation shall continue indefinitely in respect
of the applicable claim until it is finally resolved.

          7. Changes in Capital Stock. If, and as often as, there is any change in the capital stock of
the Company by way of a stock split, stock dividend, combination or reclassification, or through a
merger, consolidation, reorganization or recapitalization, or by any other means, appropriate
adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby
shall continue with respect to the capital stock as so changed.

          8. Rule 144 Reporting. With a view to making available the benefits of certain rules and
regulations of the Commission which may at any time permit the sale of the Investor Securities to
the public without registration, or pursuant to a registration on Form S-3, the Company shall at
all times after ninety (90) days after any registration statement covering a public offering of
securities of the Company under the Securities Act shall have become effective, the Company agrees
to:

	 	(A)	 	make and keep public information available, as those terms are understood and
defined in Rule 144(c) under the Securities Act;
	 
	 	(B)	 	file with the Commission in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act;
	 
	 	(C)	 	furnish to each holder of Investor Securities forthwith upon request a written
statement by the Company as to its compliance with the reporting requirements of such
Rule 144 and of the Securities Act and the Exchange Act, or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3 (at any time after the
Company so qualifies); and
	 
	 	(D)	 	furnish to each holder of Investor Securities a copy of the most recent annual
or quarterly report of the Company, and such other reports and documents filed with the
Commission by the Company, as such holder may reasonably request in availing itself of
any rule or regulation of the Commission allowing such holder to sell any Investor
Securities without registration or pursuant to Form S-3 (at any time after the Company
so qualifies to use such form); provided, that this obligation shall be deemed
satisfied if such reports and documents are publicly available on the Commission’s
EDGAR or IDEA systems (or any successor systems thereto).

          9. Representations and Warranties of the Company. The Company represents and warrants to the
Investors as follows:

12

 

               (a) The execution, delivery and performance of this Agreement by the Company have been duly
authorized by all requisite corporate action and will not violate any provision of law, any order
of any court or other agency of government, the charter or By-laws of the Company or any provision
of any indenture, agreement or other instrument to which it or any or its properties or assets is
bound, conflict with, result in a breach of or constitute (with due notice or lapse of time or
both) a default under any such indenture, agreement or other instrument or result in the creation
or imposition of any lien, charge or encumbrance of any nature whatsoever upon any of the
properties or assets of the Company or its subsidiaries.

               (b) This Agreement has been duly executed and delivered by the Company and constitutes the
legal, valid and binding obligation of the Company, enforceable in accordance with its terms,
except as the enforceability thereof may be limited by bankruptcy, insolvency, moratorium,
reorganization or other similar laws affecting the enforcement of creditors’ rights generally and
to judicial limitations on the enforcement of the remedy of specific performance and other
equitable remedies and except for the indemnification provisions contained herein as limited by
applicable federal or state securities laws.

          10. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of
the Parties and their respective successors, heirs, personal representatives and permitted assigns.
This Agreement and the rights and duties of the Company set forth herein may be freely assigned by
the Company without the consent of the Investors or the holders of the Investor Securities. This
Agreement and the rights and duties of the Investors set forth herein shall not be assigned by any
Investor, in whole or in part, except to Permissible Transferees. All covenants and agreements of
holders of Investor Securities shall bind any and all Permissible Transferees of Investor
Securities, and the Company shall not transfer on its records any such Investor Securities unless
the Permissible Transferee shall have first delivered to the Company (in a form acceptable to the
Company) the written agreement of the Permissible Transferee to become a Party to this Agreement as
a holder of Investor Securities.

          11. Limitations on Subsequent Registration Rights; Termination of Prior Registration Rights.

               (a) From and after the date of this Agreement, the Company shall not, without the prior
written consent of the holders of a majority of the Investor Securities then outstanding, enter
into any agreement with any holder or prospective holder of any securities of the Company that
would grant to such holder or prospective holder the right, except to employees of the Company with
respect to registrations on Form S-8 (or any successor forms thereto), to request the Company to
register or include in any registration any securities of the Company.

               (b) Each of the Replidyne Investors hereby acknowledges that all of its registration rights
under the Replidyne Stockholders Agreement, including those set forth in Articles 3 and 4 thereof,
are hereby terminated and shall be of no further force and effect, and that the only registration
rights relating to the capital stock of the Company that such Replidyne Investors hold are set
forth in this Agreement.

13

 

          12. Enforcement.

               (a) Remedies. If a Party shall default (and shall not have cured such default within
any applicable cure periods provided for herein) in any of its obligations under this Agreement or
if any representation or warranty made by the Company in this Agreement shall be untrue or
misleading as of the date it was made, any aggrieved Party may proceed to protect and enforce its
rights in accordance with Section 12(b), whether for the specific performance of any provision
contained in this Agreement or for an injunction or restraining order against the breach of any
such provision or for monetary damages in furtherance of the exercise of any power granted in this
Agreement, or to enforce any other legal or equitable right of such Party or to take any one or
more of such actions.

               (b) Disputes. The Parties hereby consent and agree that the State or Federal Courts
located in Ramsey County, City of St. Paul, Minnesota, shall have exclusive jurisdiction to hear
and determine any claims or disputes between the Parties pertaining to this Agreement or to any
matter arising out of or relating to this Agreement; provided, that the Parties acknowledge
that any appeals from those courts may have to be heard by a court located outside of Ramsey
County, City of St. Paul, Minnesota. The Parties expressly submit and consent in advance to such
jurisdiction in any action or suit commenced in any such court, waives any objection which they may
have based on lack of personal jurisdiction, improper venue or forum non
conveniens and hereby consent to the granting of such legal or equitable relief as is
deemed appropriate by such court.

               (c) Waiver of Jury Trial. The Parties desire that disputes arising hereunder or
relating hereto be resolved by a judge applying such applicable laws. Therefore, the Parties
hereto waive all right to trial by jury in any action, suit or proceeding brought to resolve any
dispute, whether sounding in contract, tort, or otherwise among the Parties arising out of,
connected with, related to, or incidental to the relationship established in connection with, this
Agreement.

               (d) Remedies Cumulative; Waiver. No remedy referred to herein is intended to be
exclusive, but each shall be cumulative and in addition to any other remedy referred to above or
otherwise available to any Party. No express or implied waiver by any Party of any default shall
be a waiver of any future or subsequent default. The failure or delay of any Party in exercising
any rights granted it hereunder shall not constitute a waiver of any such right and any single or
partial exercise of any particular right by any Party shall not exhaust the same or constitute a
waiver of any other right provided herein.

          13. Miscellaneous.

               (a) Whenever herein the singular number is used, the same shall include the plural where
appropriate, and words of any gender shall include each other gender where appropriate. Unless
otherwise expressly provided, the words “include”, “includes” and
“including” do not limit the preceding words or terms and shall be deemed to be followed by
the words “without limitation.” The captions and headings used in this Agreement are for
convenience only and do not in any way affect, limit, amplify or modify the provisions hereof.

14

 

               (b) All notices, requests, consents and other communications hereunder shall be in writing and
shall be delivered in person, mailed by certified or registered mail, return receipt requested, or
sent by telecopier or telex, addressed (i) if to the Company, at 651 Campus Drive, St. Paul, MN
55112, Attention: Chief Executive Officer, facsimile number 651 259-1696 and (ii) if to any holder
of Investor Securities, to such holder at such address as may have been furnished to the Company in
writing by such holder; or, in any case, at such other address or addresses as shall have been
furnished in writing to the Company (in the case of a holder of Investor Securities) or to the
holders of Investor Securities (in the case of the Company) in accordance with the provisions of
this Section.

               (c) This Agreement shall be governed by and construed in accordance with the laws of the State
of Delaware applicable to agreements entered into and to be wholly-performed in such State.

               (d) This Agreement may be amended at any time and from time to time, in whole or in part, by a
writing executed by the Company and the holders of at least 66 2/3% of the then outstanding
Investor Securities, including Easton and Maverick to the extent that such Investors hold Investor
Securities at the time of such amendment; provided, that no such amendment may materially
adversely affect or terminate the rights of any Investor under this Agreement without the written
consent of such Investor.

               (e) This Agreement may be executed by facsimile signature and in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument, it being understood that all parties need not sign the same counterpart.

               (f) If any provision of this Agreement is held to be illegal, invalid or unenforceable under
present or future laws effective during the term of this Agreement, such provision shall be fully
severable, this Agreement shall be construed and enforced as if such illegal, invalid or
unenforceable provision had never comprised a part of this Agreement, and the remaining provisions
of this Agreement shall remain in full force and effect and shall not be affected by the illegal,
invalid or unenforceable provision or by its severance from this Agreement. Furthermore, the
Parties shall negotiate in good faith to duly amend this Agreement be replacing such illegal,
invalid or unenforceable provision with a legal, valid and enforceable provision, the economic
effect of which comes as close as possible to that of such illegal, invalid or unenforceable
provision.

          14. Termination.

               (a) This Agreement shall automatically terminate as to any holder of Investor Securities at
such time when all of such holder’s Investor Securities may be sold pursuant to Rule 144 under the
Securities Act or any successor rule without restriction as to volume limitations.

               (b) This Agreement shall automatically terminate when all Investor Securities have been sold
or transferred by the holders of the Investor Securities (other than to Permissible Transferees).

15

 

          15. Silicon Valley Bank. Notwithstanding anything to the contrary set forth in the Recitals
hereto, on September 12, 2008, CSI-MN issued a warrant to purchase 13,000 shares of CSI-MN’s Series
B Preferred Stock to Silicon Valley Bank, which warrant was assigned to SVB Financial Group
(“SVB”), was assumed by the Company in connection with the Merger and became a warrant to
purchase the number of shares of Common Stock of the Company set forth on Schedule I opposite SVB’s
name (the “SVB Warrant”). Automatically upon the exercise or conversion of the SVB Warrant
by SVB (or any successors or permitted transferees or assigns under the Warrant) (the “Warrant
Holder”), and not until then, the Warrant Holder shall be deemed to be a party hereto as an
Investor and the shares represented by the SVB Warrant shall become Investor Securities hereunder.

[Remainder of page intentionally left blank; signature page follows]

16

 

     IN WITNESS WHEREOF, the parties hereto have caused this Registration Rights Agreement to be
executed as an instrument under seal as of the date first above written.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	CARDIOVASCULAR SYSTEMS, INC.	 	 	 	MAVERICK FUND II, LTD.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ David L. Martin	 	 	 	By:	 	Maverick Capital, Ltd.
	 	 	 	 	 	 	 	 	 
	 	 	Name:	 	David L. Martin	 	 	 	 	 	Its Investment Advisor
	 

	 	Title:
	 	Chief Executive Officer	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	By:	 	/s/ John T. McCafferty
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	Name:
	 	John T. McCafferty
	 

	 	 	 	 	 	 	 	 	 	Title:
	 	Limited Partner and General Counsel
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	EASTON HUNT CAPITAL PARTNERS, L.P.	 	 	 	MITSUI & CO. VENTURE PARTNERS II, L.P.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	EHC GP, L.P. its General Partner	 	 	 	By:	 	Mitsui & Co. Venture Partners, Inc.
Its General Partner
	By:	 	EHC GP, Inc., its General Partner	 	 	 	 	 	
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Richard P. Schneider	 	 	 	By:	 	/s/ Taro Inaba
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Richard P. Schneider
	 	 	 	 	 	Name:
	 	Taro Inaba
	 

	 	Title:
	 	Vice President & Treasurer
	 	 	 	 	 	Title:
	 	President and CEO
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	EASTON CAPITAL PARTNERS, LP	 	 	 	MITSUI & CO. VENTURE PARTNERS, INC.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	ECP GP, LLC

	 	 	 	 	 	 	 	 
	By:	 	ECP GP, Inc., its Manager	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Richard P. Schneider	 	 	 	By:	 	/s/ Taro Inaba
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Richard P. Schneider
	 	 	 	 	 	Name:
	 	Taro Inaba
	 

	 	Title:
	 	Vice President & Treasurer
	 	 	 	 	 	Title:
	 	President and CEO
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MAVERICK FUND, L.D.C.	 	 	 	MITSUI & CO. (U.S.A.), INC.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Maverick Capital, Ltd.	 	 	 	 	 	 	 	 
	 	 	Its Investment Advisor	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ John T. McCafferty	 	 	 	By:	 	/s/ Kenichi Hori
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	John T. McCafferty
	 	 	 	 	 	Name:
	 	Kenichi Hori
	 

	 	Title:
	 	Limited Partner and General Counsel
	 	 	 	 	 	Title:
	 	Senior Vice President
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MAVERICK FUND USA, LTD.	 	 	 	MCVP HOLDING, INC.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Maverick Capital, Ltd.	 	 	 	 	 	 	 	 
	 	 	Its Investment Advisor	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ John T. McCafferty	 	 	 	By:	 	/s/ Tsutomu Yoshida
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	John T. McCafferty
	 	 	 	 	 	Name:
	 	Tsutomu Yoshida
	 

	 	Title:
	 	Limited Partner and General Counsel
	 	 	 	 	 	Title:
	 	President and CEO

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Registration Rights Agreement to be executed as an
instrument under seal as of the date first above written.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	ITX INTERNATIONAL EQUITY CORP.	 	 	 	/s/ Brent G. Blackey
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Brent G. Blackey
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Takehito Jimbo	 	 	 	/s/ Gary M. Petrucci
	 	 	 	 	 	 	 
	 	 	Name:	 	Takehito Jimbo	 	 	 	Gary M. Petrucci
	 

	 	Title:
	 	President & CEO	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	WHITEBOX HEDGED HIGH YIELD PARTNERS, LP	 	 	 	SVB FINANCIAL GROUP
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Whitebox Hedged High Yield Advisors LLC

	 	 	 	 	 	 	 	 
	By:	 	Whitebox Advisors LLC	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Jonathan Wood	 	 	 	By:	 	/s/ Norman Cutler
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Jonathan Wood
	 	 	 	 	 	Name:
	 	Norman Cutler
	 

	 	Title:
	 	Chief Operating Officer/Director
	 	 	 	 	 	Title:
	 	Derivatives Manager
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	WHITEBOX COMBINED PARTNERS, LP	 	 	 	HEALTHCARE VENTURES VI, L.P.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Whitebox Combined Advisors LLC	 	 	 	By:	 	HealthCare Partners VI, L.P.,
its General Partner
	By:	 	Whitebox Advisors LLC	 	 	 	 	 	
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Jonathan Wood	 	 	 	By:	 	/s/ Jeffrey Steinberg
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Jonathan Wood
	 	 	 	 	 	Name:
	 	Jeffrey Steinberg
	 

	 	Title:
	 	Chief Operating Officer/Director
	 	 	 	 	 	Title:
	 	Administrative Partner
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	GDN HOLDINGS LLC	 	 	 	HEALTHCARE VENTURES VIII, L.P.
	 
	 	 	 	 	 	 	 	 	By:	 	HealthCare Partners VIII, L.P.,
	 	 	 	 	 	 	 	 	 	 	its General Partner
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Glen D. Nelson	 	 	 	By:	 	HealthCare Partners VIII, LLC,
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Glen D. Nelson
	 	 	 	 	 	its General Partner
	 

	 	Title:
	 	Governor & Chief Managing Member	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	/s/ Glen D. Nelson	 	 	 	By:	 	/s/ Jeffrey Steinberg
	 	 	 	 	 	 	 
	Glen D. Nelson	 	 	 	 	 	Name:	 	Jeffrey Steinberg
	 

	 	 	 	 	 	 	 	 	 	Title:
	 	Administrative Officer
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	/s/ John Borrell	 	 	 	IRON CITY FUND, LTD.
	 	 	 	 	 	 	 	 	 
	John Borrell
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	By:	 	Duquesne Capital Management, L.L.C.,
	 	 	 	 	 	 	 	 	 	 	its Investment Manager
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	/s/ Paul Koehn	 	 	 	By:	 	/s/ Joseph W. Haleski
	 	 	 	 	 	 	 
	Paul Koehn	 	 	 	 	 	Name:	 	Joseph W. Haleski
	 

	 	 	 	 	 	 	 	 	 	Title:
	 	Vice President
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	/s/ Robert J. Thatcher	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Robert J. Thatcher	 	 	 	 	 	 	 	 

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Registration Rights
Agreement to be executed as an instrument under seal as of the date first above written.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	JUGGERNAUT FUND, L.P.	 	 	 	SEQUEL ENTREPRENEURS’ FUND III, L.P.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Duquesne Capital Management, L.L.C.,	 	 	 	By:	 	Sequel Venture Partners III, L.L.C.,
	 	 	its Investment Manager	 	 	 	 	 	its General Partner
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Joseph W. Haleski	 	 	 	By:	 	/s/ Daniel J. Mitchell
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Joseph W. Haleski
	 	 	 	 	 	Name:
	 	Daniel J. Mitchell
	 

	 	Title:
	 	Vice President
	 	 	 	 	 	Title:	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	WINDMILL MASTER FUND, L.P.	 	 	 	TPG BIOTECHNOLOGY PARTNERS, L.P.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Duquesne Capital Management, L.L.C.,
its Investment Manager	 	 	 	By:	 	TPG Biotechnology Genpar, L.P.
	 	 		 	 	 	By:	 	TPG Biotech Advisors, LLC
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Joseph W. Haleski	 	 	 	By:	 	/s/ Clive Bode
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Joseph W. Haleski
	 	 	 	 	 	Name:
	 	Clive Bode
	 

	 	Title:
	 	Vice President
	 	 	 	 	 	Title:
	 	Vice President
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	MORGENTHALER PARTNERS, VII, L.P.	 	 	 	TPG VENTURES, L.P.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Morgenthaler Management Partners, VII, L.L.C.,
its Managing Partner	 	 	 	By:	 	TPG Ventures Genpar, L.P.
	 	 		 	 	 	By:	 	TPG Ventures Advisors, LLC
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Theodore A. Laufik	 	 	 	By:	 	/s/ Clive Bode
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Theodore A. Laufik
	 	 	 	 	 	Name:
	 	Clive Bode
	 

	 	Title:
	 	Chief Financial Officer and Managing Member
	 	 	 	 	 	Title:
	 	Vice President
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP	 	 	 	SMITHKLINE BEECHAM PLC
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Jay A. Schoenfarber	 	 	 	By:	 	/s/ V.A. Whyte
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Jay A. Schoenfarber
	 	 	 	 	 	Name:
	 	V.A. Whyte
	 

	 	Title:
	 	Attorney-in-Fact
	 	 	 	 	 	Title:
	 	Assistant Secretary
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	SEQUEL LIMITED PARTNERSHIP III	 	 	 	/s/ Edward Brown
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Edward Brown
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	Sequel Venture Partners III, L.L.C.,	 	 	 	 	 	 	 	 
	 	 	its General Partner	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Daniel J. Mitchell	 	 	 	/s/ Henry Wendt
	 	 	 	 	 	 	 
	 	 	Name:	 	Daniel J. Mitchell	 	 	 	Henry Wendt
	 

	 	Title:	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	/s/ Todd Van Horn
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Todd Van Horn
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	/s/ Lee Lutz
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Lee Lutz

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]